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is that the association signal we detected was due to the pres-
ence of regulatory rather than coding SNPs, as indeed is the
case for many autoimmune diseases.7 The data generated by
the HapMap Consortium are consistent with this hypothesis,
as they show that variants identified in our previous associa-
tion study are in strong linkage disequilibrium with several
SNPs mapping to the DSG3 promoter. The notion that alleles
affecting DSG3 regulation may be pathogenic is also in
agreement with results obtained in animal models, demon-
strating that altered DSG3 expression can affect epidermal dif-
ferentiation8 and keratinocyte cohesion.9 In this context, a
functional and genetic characterization of DSG3 regulatory ele-
ments is now required and holds the promise to identify
novel sequence variants affecting gene expression and disease
susceptibility.
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Targeted broadband ultraviolet B phototherapy
improves disorders characterized by increased
dermal matrix
DOI: 10.1111/j.1365-2133.2009.09461.x
SIR, Granuloma annulare (GA), dermatofibroma (DF) and
keloid ⁄hypertrophic scars (SC) are disorders with altered der-
mal matrix deposition for which there are currently limited
treatment options. Ultraviolet (UV) irradiation promotes deg-
radation of structural components of the dermis with induc-
tion of matrix metalloproteinases (MMPs) in normal human
skin and inhibition of collagen production.1,2 These findings
led to studies using long-wave UVA (340–400 nm; UVA1)
and psoralen plus UVA (PUVA) phototherapy to improve the
appearance of GA and SC.3,4 These treatments are traditionally
delivered using a whole body unit where both normal and
affected skin is exposed to UV irradiation. Targeted delivery
of UV therapy to lesional skin minimizes exposure of normal
skin to UV radiation and unnecessary risks such as burns or
skin cancer.5 Targeted UVB (tUVB) allows high-energy flu-
ences delivered only to lesional skin and has shown promise
in treating a range of skin diseases such as psoriasis and viti-
ligo.6,7 Based on previous studies, we investigated the efficacy
and advantages of a tUVB system in treating conditions with
increased dermal matrix.
Fifteen patients with GA (n = 5), DF (n = 4) and SC
(n = 6) were enrolled in the study. The mean age in the
groups was 62, 35 and 44 years with a mean duration of dis-
ease of 2, 8 and 18 years, respectively. The predominant skin
phototype was III (range II–VI). Patients with a prior history
of photosensitivity, active or recent systemic or topical ther-
apy, or pregnancy ⁄ lactation were excluded. UVB phototherapy
was administered by the T500· Targeted Phototherapy System
(Daavlin, Bryan, OH, U.S.A.), also called DuaLight (TheraLight
Inc., Carlsbad, CA, U.S.A.), with an emission spectrum of
290–330 nm and peaks of 302 and 312 nm.7 Localized irradi-
ation was directed at study sites through a hand-held fibre
optic cable with a square aperture of 3Æ63 cm2. For patients
with GA, similar lesional areas of skin were left untreated and
monitored as control lesions throughout the study. Treatments
were given up to three times per week for 16 weeks. Photo-
therapy was initiated with twice the minimal erythema dose
(MED)1 and was increased by 1 MED as tolerated. Clinical
response was graded on a five-point scale ()1 = worsening,
0 = no change, 1 = improved, 2 = much improved,
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3 = clear). The hardness of lesional skin was measured by
a hand-held digital durometer (scale 00, model DD-3; Rex
Durometers, Buffalo Grove, IL, U.S.A.) as previously
described.8
Overall, patients tolerated treatments well. There was signif-
icant softening of lesions at the end of treatment compared
with baseline, with an average reduction in durometer read-
ings of 11% (range 0Æ5–34%, P = 0Æ003) whereas adjacent
normal skin had an increase of 2Æ6% (P = 0Æ002). Good or
excellent response (clinical grade 2 or 3) was observed in four
patients (three GA, one DF), while nine patients (two GA, five
SC, two DF) had a mild grade 1 response, and two patients
(one SC, one DF) were nonresponders. Among the responders
(n = 13), those who received tUVB three times weekly had
better clinical outcome than those treated less frequently
(mean durometer reduction 14% vs. 7%, P = 0Æ25; mean glo-
bal response 1Æ7 vs. 1Æ0, P = 0Æ0004). The mean cumulative
treatment dose was 46 J cm)2 (range 8–61) in the group trea-
ted three times weekly, and 20 J cm)2 (range 13–25) in the
group treated less frequently.
Patients with GA had the greatest clinical response (Fig. 1)
and we chose to study this group further. Tissue was obtained
by 3-mm punch biopsies. Immunohistochemistry demon-
strated the presence of CD3+ T cells, markers of histiocytes
(CD68+), type I procollagen (SP1, PC1) and cell proliferation
(Ki67 antigen) in untreated lesions and these markers were no
longer detected post-treatment (Fig. 2). We observed a reduc-
tion in the expression of type I procollagen (P < 0Æ05) and in
collagen III synthesis (P = 0Æ12) after tUVB treatment, as
assessed by quantitative reverse transcriptase-polymerase chain
reaction. No significant changes were observed in the expres-
sion of MMP1, MMP3 and MMP9.
Our pilot study demonstrates that tUVB phototherapy may
improve the clinical appearance of disorders characterized by
increased dermal matrix such as GA, DF and SC. Few studies
have addressed the possible therapeutic efficacy of UVB on
these conditions. The clinical effects of tUVB appear to be
similar to those produced by UVA1 phototherapy, and altera-
tions in collagen synthesis may be involved as demonstrated
by immunohistochemistry in our patients with GA. Addition-
ally, the greater clinical improvement we observed in these
patients compared with the DF and SC subgroups, may partly
be due to UV-induced immunosuppression acting along with
its known antifibrotic response. Previous works demonstrated
increased number of CD3+ and CD4+ T lymphocytes in GA
lesions9 and in our study, these cells were undetectable in
lesional skin after UVB treatment.
Targeted phototherapy allows for rapid (< 30 s) delivery of
controlled doses of irradiation to selected skin without expos-
ing adjacent healthy tissues to unnecessary risks. With
additional clinical experience and treatment optimization,
tUVB may become an effective and safe therapeutic modality




Fig 1. Granuloma annulare lesions of the
elbows. Note in the right elbow the discrete
papules seen pre-treatment (a) are no longer
visible post-treatment and this response was
maintained at week 29 (b), with mild
tanning. The left elbow (c) served as a control
and papules persisted at week 29 (d). A
pre-treatment biopsy (white arrow) was taken
from the control side to avoid confounding
any potential benefits on the treated side,
while a post-treatment biopsy (black arrow)
was taken from the treated area at the end of
the study.
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A comparative study of the effects of
disposable and Volkmann spoon curettes
in the treatment of basal cell carcinoma
DOI: 10.1111/j.1365-2133.2009.09425.x
SIR, Basal cell carcinoma (BCC) is the most common skin
tumour.1 Curettage has been widely used for treatment of
BCC, especially at low-risk sites in elderly patients. We have
therefore compared modern disposable curettes (Stiefel, High
Wycombe, U.K.) with traditional Volkmann spoons. Ethical
approval for the study was obtained.
Over a 5-year period 405 BCCs in 366 patients were com-
puter randomized by tumour to treatment with disposable vs.
nondisposable curettes in a comparative prospective study. Of
the BCCs, 93% were primary tumours, 68% were < 1 cm in
diameter, 60% were superficial spreading BCCs, 37% were
nodular, and 71% were on the head and neck. Sixteen patients
had 39 tumours (randomized individually) and appear in
either or both groups. All tumours were small and well
defined with no morphoeic appearance clinically. Age, sex,
skin type, tumour size, site, type, and whether primary or
(a) (b)
(c) (d)
Fig 2. Immunohistochemistry. CD3+ T
lymphocytes were present in the periphery of
granuloma annulare (GA) lesions before
treatment (a) and were undetectable after
16 weeks of treatment (b). Procollagen (PC1)
was present in the periphery of GA lesions
before treatment (c) and was undetected after
16 weeks of treatment (d). A biopsy was not
obtained from one patient with GA who had
significant vascular comorbidities and with
lesions located on the lower limbs. Biopsies
were not obtained from patients in the
dermatofibroma (DF) and keloid ⁄hypertrophic
scar (SC) groups given the small lesional size
of the DF and the risk of worsening the SC.
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